PRPH ProPhase Labs, Inc.

NAS · US · Healthcare · Diagnostics & Research · prophaselabs.com

0.0125USD+25.00%Mkt Cap: 194906 $P/E: —17d ago

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a ra…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc Common Stock

$242.11BUSDP/E 35.5

DHR

Danaher Corporation Common Stock

$150.48BUSDP/E 38.2

NTRA

Natera, Inc. - Common Stock

Agilent Technologies, Inc. Common Stock

$47.30BUSDP/E 33.1

IQV

IQVIA Holdings, Inc. Common Stock

$42.50BUSDP/E 32.2

WAT

Waters Corporation Common Stock

$41.75BUSDP/E 107.4

ILMN

Illumina, Inc. - Common Stock

$41.23BUSDP/E 50.8

IDXX

IDEXX Laboratories, Inc. - Common Stock

$40.89BUSDP/E 36.4

MTD

Mettler-Toledo International, Inc. Common Stock

$29.78BUSDP/E 34.0

DGX

Quest Diagnostics Incorporated Common Stock

$25.75BUSDP/E 25.0

Labcorp Holdings Inc. Common Stock

$25.02BUSDP/E 25.5

Guardant Health, Inc. - Common Stock

$23.86BUSD

RVTY

Revvity, Inc. Common Stock

$16.91BUSDP/E 72.5

MEDP

Medpace Holdings, Inc. - Common Stock

$16.73BUSDP/E 35.2

ERF

Eurofins Scientific SE

$13.92BUSDP/E 26.0

CRL

Charles River Laboratories International, Inc. Common Stock

$13.85BUSD

ICLR

ICON plc - Ordinary Shares

Qiagen N.V. Common Shares

$9.24BUSDP/E 22.7

Key Statistics

Company

Market Cap194.91K USD

Enterprise Value9.29M USD

Revenue (TTM)3.85M USD

Gross Profit1.38M USD

Net Income (TTM)-14.74M USD

Revenue/Share0.29 USD

Last Price0.0125 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees19

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)0.02

PEG—

EV/EBITDA-0.80

EV/Revenue2.41

P/S0.04

P/B-0.05

EPS (TTM)-0.98

EPS (Forward)0.48

52W Range

0.01000% of range6.700

52W High6.700 USD

52W Low0.0100 USD

Profitability

Gross Margin31.85%

Oper. Margin-261.62%

EBITDA Margin0.00%

Profit Margin-339.31%

ROE-420.27%

ROA-24.62%

Growth

Revenue Growth-18.90%

Earnings Growth—

Cash Flow & Leverage

Operating CF-8.34M USD

CapEx (TTM)—

FCF Margin1235.35%

FCF Yield24382.91%

Net Debt9.10M USD

Net Debt/EBITDA-0.78

Balance Sheet

Debt/Equity2.46

Current Ratio0.05

Quick Ratio0.03

Book Value/Sh-0.22 USD

Cash/Share0.0010 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div DateMay 24, 2022

Pay DateJun 3, 2022

Splits

Last Split1:10

Split DateDec 22, 2025

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.15.59M

Float15.26M

Insiders2.13%

Institutions0.03%

Short Interest

Short Ratio0.1d

Short % Float0.71%

Short % Out.0.65%

Shares Short30.02K

Short (prev mo.)8.96K

Technical

SMA 500.0296 (-57.8%)

SMA 2000.1482 (-91.6%)

Beta0.07

S&P 52W Chg13.94%

Avg Vol (30d)104.30K

Avg Vol (10d)231.50K

Technical Indicators

RSI (14)32.3

MACD-0.0100

MACD Signal-0.0105

MACD Hist.+0.0005

BB Upper0.0445 USD

BB Middle0.0232 USD

BB Lower0.0020 USD

BB Width183.04%

ATR (14)0.0057 USD

Vol Ratio (20d)0.34x